Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2049164
Max Phase: Preclinical
Molecular Formula: C36H74N24O7
Molecular Weight: 955.15
Molecule Type: Protein
Associated Items:
ID: ALA2049164
Max Phase: Preclinical
Molecular Formula: C36H74N24O7
Molecular Weight: 955.15
Molecule Type: Protein
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O
Standard InChI: InChI=1S/C36H74N24O7/c37-19(7-1-13-50-31(38)39)25(61)56-20(8-2-14-51-32(40)41)26(62)57-21(9-3-15-52-33(42)43)27(63)58-22(10-4-16-53-34(44)45)28(64)59-23(11-5-17-54-35(46)47)29(65)60-24(30(66)67)12-6-18-55-36(48)49/h19-24H,1-18,37H2,(H,56,61)(H,57,62)(H,58,63)(H,59,64)(H,60,65)(H,66,67)(H4,38,39,50)(H4,40,41,51)(H4,42,43,52)(H4,44,45,53)(H4,46,47,54)(H4,48,49,55)/t19-,20-,21-,22-,23-,24-/m0/s1
Standard InChI Key: QVVDVENEPNODSI-BTNSXGMBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 955.15 | Molecular Weight (Monoisotopic): 954.6172 | AlogP: -7.60 | #Rotatable Bonds: 35 |
Polar Surface Area: 580.22 | Molecular Species: ZWITTERION | HBA: 13 | HBD: 25 |
#RO5 Violations: 3 | HBA (Lipinski): 31 | HBD (Lipinski): 32 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.97 | CX Basic pKa: 12.01 | CX LogP: -10.85 | CX LogD: -22.93 |
Aromatic Rings: 0 | Heavy Atoms: 67 | QED Weighted: 0.02 | Np Likeness Score: 0.17 |
1. López-Vallejo F, Martínez-Mayorga K.. (2012) Furin inhibitors: importance of the positive formal charge and beyond., 20 (14): [PMID:22682919] [10.1016/j.bmc.2012.05.029] |
Source(1):